To a human expert, looking at a swirly pink tissue sample studded with purple cells is akin to grading an exam without a name on it - the slide reveals essential information about the disease without providing other details about the patient.
Now, researchers at UC San Francisco have found a way to identify these infections in critically ill patients by pairing a generative AI analysis of medical records with a biomarker of lower respiratory infections.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has entered into an agreement to acquire SpectraWAVE, Inc., an innovator in Enhanced Vascular Imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of AI in medical imaging [3]. SpectraWAVE’s intravascular imaging and physiological assessment technologies provide advanced solutions for the treatment of patients with coronary artery disease, the most frequent type of heart disease, affecting more than 300 million people worldwide [4].
The method, called V2P (Variant to Phenotype), is designed to accelerate genetic diagnostics and aid in the discovery of new treatments for complex and rare diseases.
The team hopes their technology could help patients make faster progress during physical therapy and maintain their abilities after the end of their prescribed sessions.
The study, published in the Journal of Pharmaceutical Analysis, examines sweat's potential for real-time monitoring of hormones and other biomarkers, medication doses, and early detection of diseases such as diabetes, cancer, Parkinson's and Alzheimer's.